The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy

References

• SerugaBTempletonAJBadilloFEUnder-reporting of harm in clinical trialsLancet Oncol2016175e209e21927301048
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE) Version 4.0US Department of Health and Human Services2009 Available from: www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdfAccessed June 27, 2018
   Google Scholar
• GilbertAZieglerLMartlandMSystematic review of radiation therapy toxicity reporting in randomized controlled trials of rectal cancer: a comparison of patient-reported outcomes and clinician toxicity reportingInt J Radiat Oncol Biol Phys201592355556726068490
   PubMed Web of Science ®Google Scholar
• CastellanosEHChenSCDrexlerHHornLMaking the grade: the impact of low-grade toxicities on patient preference for treatment with novel agentsJ Natl Compr Canc Netw201513121490149526656518
   PubMed Web of Science ®Google Scholar
• KalsiTBabic-IllmanGFieldsPThe impact of low-grade toxicity in older people with cancer undergoing chemotherapyBr J Cancer2014111122224222825268369
   PubMed Web of Science ®Google Scholar
• KoehlerMFischerTKropfSFrommerJQuantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events: the somatic burden scoreSupport Care Cancer201422113089309924996832
   PubMed Web of Science ®Google Scholar
• PéronJMailletDGanHKChenEXYouBAdherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic reviewJ Clin Oncol201331313957396324062406
   PubMed Web of Science ®Google Scholar
• PitrouIBoutronIAhmadNRavaudPReporting of safety results in published reports of randomized controlled trialsArch Intern Med2009169191756176119858432
   PubMed Web of Science ®Google Scholar
• TrottiAPajakTFGwedeCKTAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology GroupLancet Oncol20078761362417543584
   PubMed Web of Science ®Google Scholar
• ThanarajasingamGAthertonPJNovotnyPJLongitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254Lancet Oncol201617566367027083333
   PubMed Web of Science ®Google Scholar
• CleelandCSZhaoFChangVTThe symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns studyCancer2013119244333434024114037
   PubMed Web of Science ®Google Scholar
• AaronsonNKAhmedzaiSBergmanBThe European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncologyJ Natl Cancer Inst19938553653768433390
   PubMed Web of Science ®Google Scholar
• SchuurhuizenCBraamseAMJKoningsIDoes severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic reviewAnn Oncol201728347848627998965
   PubMed Web of Science ®Google Scholar
• HinzAMehnertADégiCThe relationship between global and specific components of quality of life, assessed with the EORTC QLQ-C30 in a sample of 2019 cancer patientsEur J Cancer Care (Engl)2017262e12416
   Web of Science ®Google Scholar
• GiesingerJMKiefferJMFayersPMReplication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robustJ Clin Epidemiol201669798826327487
   PubMed Web of Science ®Google Scholar
• KluetzPGSlagleAPapadopoulosEJFocusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptomsClin Cancer Res20162271553155826758559
   PubMed Web of Science ®Google Scholar
• MolLOttevangerPBKoopmanMPuntCJThe prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patientsEur J Cancer20166613814327573427
   PubMed Web of Science ®Google Scholar
• SchuurhuizenCSBraamseAMBeekmanATScreening and treatment of psychological distress in patients with metastatic colorectal cancer: study protocol of the TES trialBMC Cancer20151530225903799
   PubMed Web of Science ®Google Scholar
• RingashJO’SullivanBBezjakARedelmeierDAInterpreting clinically significant changes in patient-reported outcomesCancer2007110119620217546575
   PubMed Web of Science ®Google Scholar
• OsobaDRodriguesGMylesJZeeBPaterJInterpreting the significance of changes in health-related quality-of-life scoresJ Clin Oncol19981611391449440735
   PubMed Web of Science ®Google Scholar
• KooTKLiMYA Guideline of selecting and reporting intraclass correlation coefficients for reliability researchJ Chiropr Med201615215516327330520
   PubMed Web of Science ®Google Scholar
• HinzAEinenkelJBriestSIs it useful to calculate sum scores of the quality of life questionnaire EORTC QLQ-C30?Eur J Cancer Care2012215677683
   PubMed Web of Science ®Google Scholar
• FrieseCRHarrisonJMJanzNKTreatment-associated toxicities reported by patients with early-stage invasive breast cancerCancer2017123111925193428117882
   PubMed Web of Science ®Google Scholar
• JensenKBonde JensenAGrauCThe relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnairesRadiother Oncol200678329830516524633
   PubMed Web of Science ®Google Scholar
• TrottiAColevasADSetserABaschEPatient-reported outcomes and the evolution of adverse event reporting in oncologyJ Clin Oncol200725325121512717991931
   PubMed Web of Science ®Google Scholar
• TaberneroJYoshinoTCohnALRamucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyLancet Oncol201516549950825877855
   PubMed Web of Science ®Google Scholar
• SeymourMTThompsonLCWasanHSChemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trialLancet201137797791749175921570111
   PubMed Web of Science ®Google Scholar
• PriceTJPeetersMKimTWPanitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyLancet Oncol201415656957924739896
   PubMed Web of Science ®Google Scholar
• RostiGFerrantePLedermannJHigh-dose chemotherapy for solid tumors: results of the EBMTCrit Rev Oncol Hematol200241212914011856589
   PubMed Web of Science ®Google Scholar
• BaschEReeveBBMitchellSADevelopment of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)J Natl Cancer Inst20141069dju24425265940
   PubMedGoogle Scholar